These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31871155)

  • 1. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of early stage small cell bladder cancer is not always dismal.
    Lim JH; Sundar S
    ESMO Open; 2019; 4(6):e000559. PubMed ID: 31798978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 7. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
    Garg M
    Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preneoplastic lesions and precursors of urothelial cancer].
    Knüchel-Clarke R; Gaisa NT
    Pathologe; 2016 Feb; 37(1):33-9. PubMed ID: 26811248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
    Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
    Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.
    Wang Y; Li Q; Wang J; Tong M; Xing H; Xue Y; Pan H; Huang C; Li D
    Med Oncol; 2019 Oct; 36(12):98. PubMed ID: 31664527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific types of bladder cancer].
    Bertz S; Hartmann A; Knüchel-Clarke R; Gaisa NT
    Pathologe; 2016 Feb; 37(1):40-51. PubMed ID: 26782034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.
    van de Kamp M; Meijer R; Pos F; Kerst M; van Werkhoven E; van Rhijn B; Horenblas S; Bex A
    Urol Oncol; 2018 Jun; 36(6):307.e1-307.e8. PubMed ID: 29580697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing.
    Zhang Q; Wang C; Qin M; Ye Y; Mo Y; Meng Q; Yang G; Feng G; Lin R; Xian S; Wei J; Chen S; Wang S; Mo Z
    Front Immunol; 2024; 15():1298087. PubMed ID: 38903524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
    Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
    BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.